Pharmacogenomics in psychiatry - Clinical innovation utilised by the Therapeutic Goods Administration and Food and Drug Administration.
Monash Alfred Psychiatry Research Centre, Melbourne, VIC, Australia.
Jayashri
J
Kulkarni
D001315:Australia; D015283:Citalopram / Q000494:pharmacology; D065731:Cytochrome P-450 CYP2C19 / Q000378:metabolism*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006077:Government Agencies / Q000592:standards*; D006801:Humans; D010597:Pharmacogenetics / Q000592:standards; D017410:Practice Guidelines as Topic / Q000592:standards*; D011570:Psychiatry / Q000592:standards; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards
D015283:Citalopram; D065731:Cytochrome P-450 CYP2C19; D017367:Selective Serotonin Reuptake Inhibitors